Immunotherapy plus targeted drugs after TACE for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and have confirmed hepatocellular carcinoma (HCC).
- You have at least one measurable tumor area on scans, with findings that fit specific criteria (RECIST v1.1 or mRESIST).
- Your general health is good (ECOG 0–1).
- Your liver cancer can’t be fully removed or treated with transplant/ablation, based on a tumor board decision.
- Your liver function is strong enough for treatment (Child-Pugh class A to B7).
- You can start the study treatment within 7 days after your TACE procedure, and your blood tests are at safe levels (including platelets, white blood cells, and liver kidney measures).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
This Phase 2 trial tests whether starting with atezolizumab plus bevacizumab, then using an on-demand TACE (a targeted liver artery chemo treatment) can control hepatocellular carcinoma (liver cancer). It also compares this approach to giving both medicines together with an initial TACE right away, aiming to improve tumor control and outcomes.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.